Search

The number of platelets, spreading and aggregation of platelets in plasma of 102 women treated with Ovosiston, an anticonceptive agent, were investigated. A significant increase of the number of platelets, spreading and aggregation of platelets was observed. Conclusions from isolated observations are not possible.

The plasma activity of fibrinstabilizing factor (factor XIII) in 27 women treated with Non-Ovlon an anticonceptive agent, were investigated. It was found significant differences of levels plasma activity. Conclusions from isolated observations are not possible.

Plasma activities of the fibrin-stabilising factor (Factor XIII) were tested in 60 women who were on hormonal contraceptives, different in composition (Non Ovlon and Gravistat). The activities in either group were reduced with significance, notwithstanding steroid levels. Unambiguous interpretation of that reduction proved impossible.

Platelet adhesiviness and thrombelastographic investigations in plasma by 102 women treated with Ovosiston, an anticonceptive agent were observed. A significant increase of adhesiveness and thrombelastographic variations was found. In conclusion showed abnormalities of platelet functions and thrombelastographic values point to influences by oral contraceptive agent Ovosiston. In combination with other favouring factors the risk of thromboembolism must be enhanced.

The number, proliferation, and aggregation of thrombocytes, platelet adhesiveness, and thromboblastographic values were investigated in the context of 52 women, who were on a compound hormonal contraceptive with threefold-differentiated gestagen, and of ten women with a compound hormonal contraceptive of two-fold gestagen differentiation. Tests were conducted over six months. Significant deviations from normal values were recordable. No definite conclusions, however, can be drawn from such individual observations. Disorders in thrombocyte function and change in thromboblastographic values, when considered with all their implications, are likely to suggest the presence of effects from hormonal contraceptives. Yet, both type and concentrations of oestrogens and gestagens are of minor importance to such change. Nevertheless, somewhat higher risk of thrombo-embolism should be assumed, if other conductive factors are present, at the same time.